Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591382 | 0.91 | PDE4B (0.40) | PDE4BTLR9TLR8TLR7 | |
| SCHEMBL2589502 | 0.84 | PDE4B (0.47) | PDE4BGPR119CHEK2NAMPTTLR9 | |
| SCHEMBL2587381 | 0.84 | LIPC (0.44) | GPR119CHEK2NAMPTTLR7PIK3CA | |
| SCHEMBL2592912 | 0.80 | GPR119 (0.44) | PDE4BGPR119CHEK2PIK3CDPIK3CA | |
| SCHEMBL2591241 | 0.78 | ACACB (0.53) | PDE4BGPR119CHEK2PDE4DPDE4A | |
| SCHEMBL29716410 | 0.76 | GPR119 (0.49) | GPR119CHEK2 | |
| SCHEMBL2594174 | 0.75 | KDM4E (0.35) | GPR119 | |
| SCHEMBL2583595 | 0.73 | GPR119 (0.58) | GPR119 | |
| SCHEMBL17109235 | 0.73 | RBP4 (0.43) | PDE4BGPR119NAMPTTLR9TLR8 | |
| SCHEMBL14729019 | 0.73 | ACACB (0.36) | PDE4BGPR119TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2566860-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| WO-2011140160-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | PDE4B 556/4885GPR119 1/4885CHEK2 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.